Jordi Bruix, MD

Articles

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

July 10th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

June 29th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

Dr. Bruix Discusses the Application of Regorafenib in HCC

April 28th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the application of regorafenib (Stivarga) in hepatocellular carcinoma as opposed to other tumor types.

Dr. Bruix Discusses the Success of Regorafenib in HCC

April 22nd 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

Dr. Bruix on Regorafenib in Second-Line HCC

January 17th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses positive results with the use of regorafenib as a second-line treatment in patients previously treated with sorafenib in advanced hepatocellular carcinoma.

Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib

November 17th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

Dr. Bruix on the Phase III RESORCE Trial in HCC

October 8th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.